Drug Trial Radar · NCT06799520
A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of VIS171 in Participants With Autoimmune Disease(s)
Last checked: Nov 20, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Mar 17, 2025
Primary completion
Oct 19, 2026
Study completion Feb 19, 2027
Sponsor
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
- Sponsor type
- Industry
- First posted
- Jan 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this trial is to measure safety and tolerability of subcutaneous (SC) VIS171 in combination with standard of care in participants with autoimmune disease(s). The total duration of the clinical trial for each participant will be up to approximately 9 to 12 months.
Conditions
- Systemic Lupus Erythematosus (SLE)
- Alopecia Areata (AA)
- Immune-mediated Focal Segmental Glomerulosclerosis (FSGS)
Interventions
VIS171Drug
VIS171 will be administered as a SC injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Treatment Emergent Adverse Events (TEAEs) Graded by SeverityTime frame: From first dose of the study drug up to end of the study (up to Week 45)
Locations
6 sites in 4 countries. Site status is shown where the registry gives one.
Visterra Investigational Site
Sofia, Bulgaria
Visterra Investigational Site
Chisinau, Moldova
Visterra Investigational Site
Bucharest, Romania
Visterra Investigational Site
Cluj-Napoca, Romania
Visterra Investigational Site
Barcelona, Spain
Visterra Investigational Site
Granada, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.